JAK3 inhibitor VI is a mutant specific inhibitor for epidermal growth factor receptor with the gatekeeper mutation T790M

Table 1 List of kinase inhibitors used in a screening for compounds effective on epidermal growth factor receptor T790M/L858R

Target	Compound name
AK	ABT-702
AKT (PKB)	Akt Inhibitor IV, Akt Inhibitor VIII, Akt Inhibitor XI
AMPK	compound C
ATM	ATM/ATR kinase inhibitor, ATM kinase inhibitor
Aurora kinase	Aurora kinase/CDK inhibitor, aurora kinase inhibitor II, Aurora kinase inhibitor III
Bcr-abl	AG957
BTK	LFM-A13, terreic acid
CAMKII	KN-93, KN-62, Lavendustin C
CDK	Kenpaullone, purvalanol A, Olomoucine, Alsterpaullone, Cdk1/2 inhibitor III, Cdk2/9 inhibitor, NU6102, Cdk4 inhibitor, NSC625987
Chk	SB218078, Isogranulatimide, Chk2 inhibitor, Chk2 inhibitor II
CK	Ellagic acid (dihydrate), TBB, DMAT, D4476
Clk	TG003
DGK	Diacylglycerol kinase inhibitor II
DNA-PK	IC60211
eEF2 kinase	TX-1918
EGFR	BPIQ-II, AG1478, AG490
FGFR	SU4984, SU5402
Flt-3	Flt-3 Inhibitor
Fms	cFMS Receptor Inhibitor
Fyn	SU6656
GSK	GSK-3 inhibitor IX, 1-Azakenpaullone, Indirubin-3’-monoxime
HER2	AG825
IGF-IR	AG1024, AGL 2263
IKK	BMS-345541, IKK-2 inhibitor VI
IRAK	IRAK-1/4 inhibitor
JAK	JAK Inhibitor I, JAK3 Inhibitor VI
JNK	SP600125, JNK inhibitor VIII
Lck	Damnacanthal, PP2
MAPK	ERK inhibitor II
MEK	PD98059, U-0126, MEK inhibitor I
Met	SU11274
MLCK	ML-7
p38 MAPK	SB202190, SB239063
PDGFR	AG1296, SU11652, PDGF receptor inhibitor V, PDGF receptor inhibitor IV
PI3K	LY-294002, Wortmannin
PKA	H-89, 4-cyano-3-methylisoquinoline
PKC	Bisindolymaleimide I, Go7874
PKG	Rp-8-CPT-cGMPS, KT5823
PKR	PKR inhibitor
Raf	RAF1 kinase inhibitor I, ZM 336372
ROCK	H-1152, Y-27632
Hsp90	radicicol
Src	PP1 analog
Syk	Syk inhibitor
TGF-bRI	SB431542, TGF-beta RI kinase inhibitor II
Tpl2	Tpl2 kinase inhibitor
TrKA	TrkA inhibitor
VEGFR	VEGFR receptor inhibitor II, VEGF recptor 2 inhibitor I, SU1498

AK: Adenosine kinase; AKT(PKB): Protein kinase B; AMPK: 5’-adenosine monophosphate-activated protein kinase; ATM: Ataxia telangiectasia mutated; Aurora: Aurora kinase; Bcr-abl: Breakpoint cluster region-Abelson fusion kinase; BTK: Bruton’s tyrosine kinase; CAMKII: Calcium/calmodulin-dependent protein kinase II; CDK: Cyclin-dependent kinase; Chk: Checkpoint kinase; CK: Casein kinase; Clk: Cdc2-like kinase; DGK: Diacylglycerol kinase; DNA-PK: DNA-dependent protein kinase; eEF2 kinase: Eukaryotic elongation factor 2 kinase; EGFR: Epidermal growth factor receptor; FGFR: Fibroblast growth factor receptor; Flt-3: Fms-related tyrosine kinase 3; Fms: Feline McDonough sarcoma (Colony-stimulating factor-1 receptor); GSK: Glycogen synthase kinase; HER2: Human epidermal growth factor receptor 2; IGF-IR: Insulin-like growth factor I receptor; IKK: IκB kinase; IRAK: Interleukin-1 receptor-associated kinase; JAK: Janus kinase; JNK: Jun N-terminal kinase; Lck: Lymphocyte-specific protein tyrosine kinase; MAPK: Mitogen activated protein kinase; MEK: Mitogen-activated protein/extracellular signal-regulated kinase kinase; MLCK: Myosin light chain kinase; p38 MAPK: P38 mitogen-activated protein kinase; PDGFR: Platelet-derived growth factor receptor; PI3K: Phosphatidylinositol-4-Kinase; PKA: Protein kinase A; PKC: Protein kinase C; PKG: Protein kinase G; PKR: Double-stranded RNA-activated protein kinase; Raf: Rapidly accelerated fibrosarcoma; ROCK: Rho-associated protein kinase; Hsp90: Heat shock protein; Syk: Spleen tyrosine kinase; TGF-bRI: Transforming growth factor-beta type I receptor; Tpl2: Tumor progression locus 2; TrKA: Tyrosine kinase receptor A (tyrosine kinase receptor for nerve growth factor); VEGFR: Vascular endothelial growth factor receptor.